News | May 06, 2010

Surgery Too Soon After Stenting Raises Heart Risks

May 6, 2010 – Patients who can postpone noncardiac surgery for at least six weeks after receiving a coronary stent are less likely to suffer reduced blood flow to the heart, heart attack and death than those who have surgery sooner. This was the finding of Scottish researchers in Circulation: Cardiovascular Interventions, an American Heart Association journal.

Stents are used in more than 90 percent of angioplasty patients in Scotland, according to the study. In the broad retrospective study, researchers found that 42 percent of patients undergoing noncardiac surgery within six weeks of stent implantation were more likely to suffer heart complications, including decreased blood flow to the heart (ischemia), heart attack and death. In comparison, these complications occurred in 13 percent of patients whose surgeries were performed beyond six weeks post-implantation.
The risk of heart problems following noncardiac surgery was even greater among patients whose stents were inserted as treatment for a recent heart attack (occurring in 65 percent of patients) than among those with stable but chronic disease (occurring in 32 percent of patients). The type of stent — bare metal vs. drug-eluting — didn't affect risk, which was similar for the first two years after stent implantation.

The researchers examined records for 1,953 patients, with an average age of 64, who received coronary stents in Scotland between April 2003 and March 2007. They used hospital admission data and information from the Scottish Coronary Revascularization Register.

Previous studies have found that patients who underwent noncardiac surgery within four to six weeks of bare-metal stent implantation had a greater incidence of serious heart complications. However, those studies did not clarify how long the risk persisted after stent implantation and whether it was the same in patients with drug-eluting stents.

"These findings have important implications for a large number of patients," said Nicholas L.M. Cruden, Ph.D., M.B., first author of the study and cardiology lecturer at the University of Edinburgh in Scotland. "In the current study, 4.4 percent of patients undergoing percutaneous coronary intervention underwent noncardiac surgery within one year of coronary stent implantation."

A Health Services Research Grant from the Scottish government's Chief Scientist Office funded this study.

Stent Stats from the American Heart Association

• More than 70 percent of coronary angioplasty procedures in the United States also include stenting.

• In 2006, about 65 percent of percutaneous coronary intervention (PCI) procedures were performed on men, and approximately 50 percent were performed on people age 65 or older.

• In 2006, an estimated 1,313,000 PCI procedures were performed in the United States.

• In 2006, approximately 76 percent of stents implanted during PCI were drug-eluting, compared with 24 percent bare-metal stents.

• In 2006, there were 652,000 PCI procedures with stents – 425,000 in men, 227,000 in women.

For more information: www.americanheart.mediaroom.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init